AI-enabled pathology company PathAI has entered into a multiyear drug discovery partnership with pharma giant GlaxoSmithKline.
The agreement will focus on advancing clinical trials and drug development in oncology and for nonalcoholic steatohepatitis (NASH), an aggressive type of fatty liver disease that can lead to serious scarring and liver failure.
"Our partnership will combine GSK and PathAI...
Qure.ai scored FDA 510(k) clearance for its artificial intelligence algorithm that assists providers in placing breathing tubes.
The clearance, which officially came down in late December, is the company's third 510(k). The two previous FDA green lights were regarding its brain CT scan product.
Using chest x-rays, the qXR-BT algorithm can analyze the position of the breathing tube. It automates...
Viome Life Sciences, maker of at-home tests for gut and immune system health, is expanding its partnership with global pharma company GlaxoSmithKline to research and potentially develop interventions for some cancers and autoimmune diseases.
The collaboration will allow the companies to study the connection between the gut microbiome and some chronic diseases, like autoimmune disorders. Viome...
Belfast-based data analytics company Diaceutics announced yesterday that it will seek listing on London’s junior stock exchange, the Alternative Investment Market (AIM).
The firm, which serves the global pharmaceutical industry, plans to float on Thursday with an expected market capitalisation of around £53m ($70m).
Diaceutics said in a press release that it has already raised £17m ($22.5m)...
By and large, Q3 2018 was a slow and steady quarter for pharma moves in digital health, at least in terms of publicly disclosed operations. At events during the quarter, the likes of Johnson & Johnson, AstraZeneca, Novartis and Sanofi discussed digital therapeutics and expressed a healthy mixture of skepticism and enthusiasm for the space.
“These technologies have a tremendous opportunity to...
23andMe on Wednesday announced that GlaxoSmithKline has invested $300 million to gain exclusive access to the genetic testing startup’s DNA database.
The deal comes as GlaxoSmithKline amid reports that GSK is weighing the possibility of a company breakup and investors contending that synergies between consumer markets and big pharma are inherently limited and that GSK’s pharmaceuticals business...
Earnings reports shared by neurostimulation and digital medicine company NeuroMetrix during a Q2 investors’ call showed a slight drop in total revenue as the company is preparing to place its marketing weight behind the launch of its updated wearable pain relief product, Quell. However, the company remained profitable during the quarter thanks to sales of its other product, DPNCheck.
Dr. Shai N....
Launchpad’s new arrivals. San Francisco-based accelerator Launchpad Digital Health has added eight new digital health startups to its 12-month program: Agathos, a care variation and cost measurement platform; Addicaid, a virtual addiction recovery program; Elemeno Health, virtual coach software for healthcare teams; Happy Couple, a daily relationship bonding app; Mentia, a therapeutic support...
GlaxoSmithKline has made a hire signaling its commitment to digital health. Karenann Terrell, former Chief Information Officer at Walmart, will start at GSK in the newly created role of Chief Digital and Technology Officer.
“The impact of technology on the healthcare industry is accelerating and requires us to rethink our approach,” CEO Emma Walmsley said in a statement. “As a member of the...
When Apple announced ResearchKit in March 2015, and unveiled the first five apps to test-drive the company’s new approach to clinical research, the announcement made a big splash. And indeed, in the weeks following, those apps posted incredible recruitment figures: for instance, Parkinson’s emPower study saw 5,500 sign-ups by day two and ended up with more than 18,000 participants.
But there...
